NCT03016819: An ongoing trial by Advenchen Laboratories, LLC
This trial is ongoing. It must report results 2 weeks, 1 day from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03016819 |
|---|---|
| Title | A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 15, 2017 |
| Completion date | Dec. 31, 2024 |
| Required reporting date | Dec. 31, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |